Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.30 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16576221 | 1.00 | GAPDH (0.34) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL17958878 | 1.00 | GAPDH (0.34) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL17972463 | 1.00 | GAPDH (0.34) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL26976634 | 1.00 | GAPDH (0.34) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL21418943 | 0.93 | POLB (0.36) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL17972480 | 0.93 | POLB (0.36) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL16576220 | 0.93 | POLB (0.36) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL14102275 | 0.93 | POLB (0.36) | GAPDHMEN1USP2POLBKMT2A | |
| SCHEMBL15281799 | 0.85 | POLB (0.41) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL13592886 | 0.85 | POLB (0.41) | MEN1USP2POLBKMT2AP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | GAPDH 473/4885MEN1 3716/4885USP2 4321/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | GAPDH 1138/4885MEN1 1167/4885USP2 4851/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | GAPDH 193/4885MEN1 3476/4885USP2 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.